|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST1H2BJ |
Gene summary for HIST1H2BJ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST1H2BJ | Gene ID | 8970 |
| Gene name | H2B clustered histone 11 | |
| Gene Alias | H2B/r | |
| Cytomap | 6p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0001906 | UniProtAcc | A0A024RCJ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8970 | HIST1H2BJ | CCI_2 | Human | Cervix | CC | 1.21e-16 | 9.66e-01 | 0.5249 |
| 8970 | HIST1H2BJ | CCI_3 | Human | Cervix | CC | 3.04e-05 | 2.06e-01 | 0.516 |
| 8970 | HIST1H2BJ | Tumor | Human | Cervix | CC | 9.00e-07 | 1.88e-01 | 0.1241 |
| 8970 | HIST1H2BJ | sample3 | Human | Cervix | CC | 8.77e-10 | 1.41e-01 | 0.1387 |
| 8970 | HIST1H2BJ | T3 | Human | Cervix | CC | 1.81e-04 | 1.33e-01 | 0.1389 |
| 8970 | HIST1H2BJ | LZE4T | Human | Esophagus | ESCC | 6.07e-05 | 4.33e-01 | 0.0811 |
| 8970 | HIST1H2BJ | LZE7T | Human | Esophagus | ESCC | 4.04e-05 | 3.35e-01 | 0.0667 |
| 8970 | HIST1H2BJ | LZE20T | Human | Esophagus | ESCC | 2.68e-08 | 3.16e-01 | 0.0662 |
| 8970 | HIST1H2BJ | LZE21D1 | Human | Esophagus | HGIN | 1.61e-02 | 3.14e-01 | 0.0632 |
| 8970 | HIST1H2BJ | LZE22T | Human | Esophagus | ESCC | 6.11e-09 | 7.61e-01 | 0.068 |
| 8970 | HIST1H2BJ | LZE24T | Human | Esophagus | ESCC | 3.98e-04 | 3.13e-01 | 0.0596 |
| 8970 | HIST1H2BJ | LZE21T | Human | Esophagus | ESCC | 3.77e-05 | 9.27e-01 | 0.0655 |
| 8970 | HIST1H2BJ | P1T-E | Human | Esophagus | ESCC | 2.29e-23 | 1.50e+00 | 0.0875 |
| 8970 | HIST1H2BJ | P2T-E | Human | Esophagus | ESCC | 4.16e-22 | 4.53e-01 | 0.1177 |
| 8970 | HIST1H2BJ | P4T-E | Human | Esophagus | ESCC | 9.90e-16 | 5.28e-01 | 0.1323 |
| 8970 | HIST1H2BJ | P5T-E | Human | Esophagus | ESCC | 4.27e-02 | 1.10e-01 | 0.1327 |
| 8970 | HIST1H2BJ | P8T-E | Human | Esophagus | ESCC | 4.87e-07 | 2.14e-01 | 0.0889 |
| 8970 | HIST1H2BJ | P9T-E | Human | Esophagus | ESCC | 3.04e-10 | 4.36e-01 | 0.1131 |
| 8970 | HIST1H2BJ | P10T-E | Human | Esophagus | ESCC | 2.08e-17 | 4.94e-01 | 0.116 |
| 8970 | HIST1H2BJ | P11T-E | Human | Esophagus | ESCC | 5.52e-06 | 3.99e-01 | 0.1426 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST1H2BJ | SNV | Missense_Mutation | c.178N>C | p.Met60Leu | p.M60L | P06899 | protein_coding | deleterious_low_confidence(0.01) | benign(0.039) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
| HIST1H2BJ | insertion | Frame_Shift_Ins | novel | c.18_19insCACGCCGTGTCCGAGGG | p.Ser7HisfsTer19 | p.S7Hfs*19 | P06899 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| HIST1H2BJ | SNV | Missense_Mutation | c.340N>A | p.Glu114Lys | p.E114K | P06899 | protein_coding | tolerated_low_confidence(0.07) | benign(0.124) | TCGA-AZ-6599-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HIST1H2BJ | SNV | Missense_Mutation | c.80N>T | p.Gly27Val | p.G27V | P06899 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.821) | TCGA-F4-6461-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| HIST1H2BJ | SNV | Missense_Mutation | novel | c.116N>A | p.Ser39Tyr | p.S39Y | P06899 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.781) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| HIST1H2BJ | SNV | Missense_Mutation | c.48N>T | p.Lys16Asn | p.K16N | P06899 | protein_coding | deleterious_low_confidence(0.01) | benign(0.217) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
| HIST1H2BJ | SNV | Missense_Mutation | c.144N>C | p.Gln48His | p.Q48H | P06899 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.968) | TCGA-50-6591-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| HIST1H2BJ | SNV | Missense_Mutation | novel | c.278N>C | p.Arg93Thr | p.R93T | P06899 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.982) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HIST1H2BJ | SNV | Missense_Mutation | c.10N>A | p.Pro4Thr | p.P4T | P06899 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-CV-6436-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| HIST1H2BJ | SNV | Missense_Mutation | novel | c.310N>T | p.Pro104Ser | p.P104S | P06899 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-WA-A7GZ-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |